Horizon Pharma (HZNP) Tops Q2 EPS by 7c

Go back to Horizon Pharma (HZNP) Tops Q2 EPS by 7c

Horizon Pharma plc Announces Record Second Quarter 2015 Financial Results

August 7, 2015 7:00 AM EDT

DUBLIN, IRELAND -- (Marketwired) -- 08/07/15 -- Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced its second-quarter 2015 financial results today.

Quarterly Financial Highlights

(in millions except for per share amounts and % % percentages) Q2 15 Q2 14 Change 1H 15 1H 14 Change ------- ------- ------ ------- ------- ------ Net sales $ 172.8 $ 66.1 161 $ 286.0 $ 118.0 142 Net income (loss) 31.8 (27.8) NM 12.3 (234.0) NM Adjusted non-GAAP net income 61.9 19.8 213 86.4 26.8 222 Adjusted EBITDA 76.1 21.5 254 108.5 30.2 259 Earnings (loss) per share - basic $ 0.21 $ (0.38) NM $ 0.09 $ (3.34) NM Adjusted non-GAAP earnings per share - basic 0.41 0.27 52 0.62 0.38 63 Earnings (loss)... More

Depomed Sends Letter to Horizon Pharma

August 7, 2015 6:30 AM EDT

NEWARK, Calif., Aug. 7, 2015 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) ("Depomed" or the "Company") today announced that it has sent the following letter to Horizon Pharma plc (NASDAQ: HZNP) ("Horizon"):

August 7, 2015

Timothy P. Walbert Chairman of the Board, President and Chief Executive OfficerHorizon Pharma plcConnaught House, 1st Floor, 1 Burlington Road Dublin 4, Ireland 

Dear Tim,  

In our... More